About Avalyn Pharma Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.avalynpharma.com
Frequently Asked Questions
What is the 52-week range for AVLN?
The 52-week high is $40.17 and the 52-week low is $24.15.
What is the P/E ratio for AVLN?
The P/E ratio data is currently unavailable.
What is the dividend yield for AVLN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for AVLN over the last few months:
Latest AVLN News
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60
Raymond James analyst Tiago Fauth initiates coverage on Avalyn Pharma (NASDAQ:AVLN) with a Outperform rating and announces Price Target of $60.
Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey
Avalyn Pharma (AVLN) is back on investor screens after Respiratory Research published full Phase 1 data for AP02, its inhaled nintedanib program for idiopathic pulmonary fibrosis, validating Avalyn’s direct-to-lung delivery approach. Avalyn Pharma’s share price sits at US$32.45 after a 1-day share price return of 2.62%, which partly offsets a 30-day share price return that declined 15.43%. However, the 90-day and year-to-date share price returns of 7.84% and 10.04% suggest momentum has been...
Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerability Findings support continued advancement of AP02 for idiopathic pulmonary fibrosis (IPF); enrollment is on track in AURA Phase 2 trial with topline data expected late 2027 BOSTON, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pi
Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach
Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerabilityFindings support continued
Avalyn Appoints Robert J. Meyer, MD, to its Board of Directors
BOSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced the appointment of Robert (Bob) J. Meyer, MD, a distinguished pulmonary physician and former senior U.S. Food and Drug Administration (“FDA”) leader, to its Board of Directors (the “Board”). Dr. Meyer most recently served as Princi
Avalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Avalyn Pharma Inc. (AVLN) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:50 PM EDTCompany ParticipantsLyn Baranowski - CEO,...
Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases, today announced Avalyn management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City on September 14, 2026, at 1:50-2:25 p.m. ET. Access to the live webcast of this event, and the archived recording, will be po
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe disease Patient survey findings suggest that clear communication, transparent discussions of potential benefits and risks, and efforts to reduce logistical burden may support engagement in future pulmonary fibrosis clinical studies BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the tr
Avalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
In silico modeling predicts robust AP01 distribution in healthy and fibrotic lungs, even in severe diseasePatient survey findings suggest that clear communication, transparent discussions of potential benefits and
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Meyer Robert J. | +31,182 | - | - |
| 2026-05-01 | FMR LLC | -377,948 | - | - |
| 2026-05-01 | FMR LLC | -225,843 | - | - |
| 2026-05-01 | FMR LLC | -872,868 | - | - |
| 2026-05-01 | FMR LLC | -80,291 | - | - |
| 2026-05-01 | FMR LLC | -727,585 | - | - |
| 2026-05-01 | FMR LLC | +377,948 | - | - |
| 2026-05-01 | FMR LLC | +225,843 | - | - |
| 2026-05-01 | FMR LLC | +872,868 | - | - |
| 2026-05-01 | FMR LLC | +80,291 | - | - |
| 2026-05-01 | FMR LLC | +727,585 | - | - |
| 2026-05-01 | Novo Holdings A/S | -12,558,081 | - | - |
| 2026-05-01 | Novo Holdings A/S | -5,587,603 | - | - |
| 2026-05-01 | Novo Holdings A/S | -25,899,284 | - | - |
| 2026-05-01 | Novo Holdings A/S | -1,986,369 | - | - |
| 2026-05-01 | Novo Holdings A/S | -18,000,000 | - | - |
| 2026-05-01 | Novo Holdings A/S | +555,555 | $18 | $9,999,990 |
| 2026-05-01 | Novo Holdings A/S | +3,327,734 | - | - |
| 2026-05-01 | Carroll Jill | -9,418,561 | - | - |
| 2026-05-01 | Carroll Jill | -27,309,719 | - | - |
| 2026-05-01 | Carroll Jill | +277,778 | $18 | $5,000,004 |
| 2026-05-01 | Carroll Jill | +489,486 | - | - |
| 2026-05-01 | Carroll Jill | +1,419,298 | - | - |
| 2026-05-01 | George Simeon | -9,418,560 | - | - |
| 2026-05-01 | George Simeon | -6,827,429 | - | - |
| 2026-05-01 | George Simeon | -9,418,561 | - | - |
| 2026-05-01 | George Simeon | -27,309,719 | - | - |
| 2026-05-01 | George Simeon | +277,777 | $18 | $4,999,986 |
| 2026-05-01 | George Simeon | +489,486 | - | - |
| 2026-05-01 | George Simeon | +354,824 | - | - |
| 2026-05-01 | George Simeon | +277,778 | $18 | $5,000,004 |
| 2026-05-01 | George Simeon | +489,486 | - | - |
| 2026-05-01 | George Simeon | +1,419,298 | - | - |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | -4,060,259 | - | - |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | -20,482,289 | - | - |
| 2026-05-01 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. | +1,275,486 | - | - |
| 2026-04-30 | Carlson Douglas R | +211,975 | - | - |
| 2026-04-30 | Lavelle Erin | +26,978 | - | - |
| 2026-04-29 | Golden Adam H. | +254,891 | - | - |
| 2026-04-29 | Congleton Jon | +26,978 | - | - |
| 2026-04-29 | Rhodes Melissa | +211,975 | - | - |
| 2026-04-29 | Haviland Kate | +26,978 | - | - |
| 2026-04-29 | Lazarus Howard | +211,975 | - | - |
| 2026-04-29 | Baranowski Lyn | +501,033 | - | - |
| 2026-04-29 | Turner Heather D | +26,978 | - | - |